Elevated intracranial pressure (ICP) is a common clinical condition in critically ill patients with neurological injuries such as traumatic brain injury, intracerebral hemorrhage, and acute ischemic stroke. Elevated ICP is often caused by cerebral edema, a swelling of the brain that is largely dependent on primary pathology and intracellular changes.1 The Monro-Kellie doctrine states that the sum of volumes of cerebrospinal fluid, brain, and blood is constant and that an increase in any of the intracranial compartments should be balanced by a decrease in the other components. As the skull is an inflexible, enclosed space, inability to achieve pressure-volume equilibrium results in intracranial hypertension and ischemia. The normal adult ICP ranges from 5 to 15 mm Hg, and an ICP greater than 20 mm Hg indicates intracranial hypertension requiring treatment.2 Elevated ICP is associated with worse clinical outcomes; therefore, appropriate treatment should be initiated immediately.1Options for the treatment of intracranial hypertension include sedation, neuromuscular blockade, hyperventilation, hyperosmolar therapy, hypothermia, and surgical decompression. Hyperosmolar therapy is one of the most commonly employed strategies for reducing ICP by targeting cerebral edema and creating an osmotic gradient that decreases intracranial water content. Currently, mannitol and hypertonic saline (HTS) are the most studied and widely used hyperosmolar agents. Understanding the characteristics of these hyperosmolar agents is critical to ensure the efficacy and safety of therapy. Additionally, new literature evaluating the relative effectiveness of mannitol and HTS has become available in recent years. This review provides an overview of hyperosmolar therapy, with a focus on mannitol and HTS, for the management of intracranial hypertension.Mannitol works as a direct osmotic diuretic, reducing cerebrospinal fluid and brain water by creating an osmotic gradient across the blood-brain barrier (BBB). Redistribution of cerebral plasma volume results in cerebral vasoconstriction and decreased ICP. It also transiently increases cerebral blood flow by decreasing blood viscosity. Mannitol has a reflection coefficient of 0.9, indicating near impermeability to passive membrane transport across the BBB. Although mannitol is not completely excluded from passive transport, this high reflection coefficient contributes to its mechanism of action in drawing water from brain tissue into the vasculature.3 Reduction in ICP occurs rather rapidly, within 15 to 30 minutes of administration, and lasts for 1.5 to 6 hours. Typical dosing of mannitol for reduction of ICP is 0.5 to 1.5 g/kg of body weight, although doses up to 2 g/kg have been evaluated.4,5 Commercially, mannitol is available in 20% intravenous infusion bags and 25% intravenous injection vials.Mannitol therapy warrants additional considerations in administration. Mannitol is typically given as a bolus dose over 5 to 20 minutes rather than continuous infusion to avoid rebound elevation in ICP associated with prolonged therapy.6 At low temperatures, mannitol tends to form crystals. Before administration, mannitol solution must be carefully examined, and it should not be administered if crystals are observed. Instead, the container can be warmed to dissolve precipitates. A 0.22-μm in-line filter must be used when infusing mannitol to avoid the accidental injection of crystals.7 Although administration via central catheter was typically suggested in the past, evidence for the risk of extravasation with mannitol is not well reported in the literature. A recent retrospective study by Mesghali et al8 reported no incidences of extravasation among patients receiving mannitol via peripheral catheters. Considering the urgent nature of hyperosmolar therapy, clinicians may safely administer mannitol through a peripheral intravenous catheter, especially in the emergency department and intensive care unit.Despite its effectiveness and wide utilization in the reduction of ICP, mannitol is associated with several adverse events. Upon intravenous administration, mannitol remains primarily in the extracellular space and then is rapidly excreted through the kidneys, with less than 10% of the dose being reabsorbed.7,9 Therefore, in patients with preexisting renal impairment, mannitol can quickly accumulate in the circulation and may precipitate acute kidney injury (AKI). Excessive diuresis can also lead to decreased renal perfusion, contributing to worsening AKI.9 Mannitol is associated with both hypervolemia and hypovolemia. At first, mannitol rapidly expands intravascular volume by increasing serum osmolarity. Volume overload increases the risk of pulmonary edema or acute decompensated heart failure in high-risk patients.5,9 Subsequently, mannitol exerts its potent diuretic effects by rapidly removing intravascular volume, resulting in hypovolemia and hypotension. Excessive loss of water and electrolytes, in addition to AKI, leads to electrolyte imbalances, including hypokalemia or hyperkalemia, hyponatremia or hypernatremia, and hypochloremia.9 Perhaps the most troublesome complication associated with mannitol administration is rebound elevation in ICP. As indicated in its reflection coefficient, mannitol is not entirely impermeable to the BBB. When mannitol molecules cross the BBB, the osmotic gradient has the potential to pull water into the brain, resulting in rebound cerebral edema and elevation of ICP.2,6,9 The risk of adverse events increases when mannitol is administered for an extended period. Therefore, careful monitoring and tapering of the treatment are necessary to avoid such complications.To recognize potential adverse events associated with mannitol administration, clinicians must be vigilant in monitoring. Serum osmolarity and osmolar gap have been used to predict the risk of AKI in patients receiving mannitol therapy. Serum osmolarity exceeding 320 mOsm/L and an...